GSK kidney cancer drug approved in U.S.

GlaxoSmithKline's Votrient has been approved in the U.S. by the FDA to treat the most common form of kidney cancer.07/10/2018

Source: Kidney Cancer Association - July 10, 2018 Category: Urology & Nephrology Source Type: news